THEME DESCRIPTION:

There are more life-changing therapies in development for people living with rare diseases than ever before, yet at our current pace it will still take decades to cover all our unmet needs. The rare disease community still faces a number of challenges in accessing authorised therapies, which indicates that the system in its current design is not functioning to the benefit of all, particularly those people living with a rare disease.

How can we improve the functioning of the system by 2030? What are the solutions to ensure the sustainable development of therapies that are truly available to all? This theme will examine the different aspects of the system which need significant change.
SESSION 0501: Friday 15th May 2020, 14:00 – 15:30

**Rare Diseases in Numbers: What do they mean?**

Chair: Avril Daly, CEO, Retina International; Vice-President, EURORDIS

---

SESSION 0502: Friday 15th May 2020, 16:30 – 18:00

**Financing Rare Disease Therapies Development – Is the Current Model Fit for Purpose?**

Chair: Dimitrios Athanasiou, World Duchenne Organisation

---

SESSION 0503: Saturday 16th May 2020, 09:00 – 10:30

**New Disruptive Technologies: How can we prepare Healthcare Systems?**

Chair: Dr. Mariette Driessens, Policy Officer, VSOP (Dutch Genetic Alliance)

---

SESSION 0504: Saturday 16th May 2020, 11:00 – 12:30

**From Research to Access: Is a European Collaborative Approach Possible?**

Chair: TBC

---

SESSION 0505: Saturday 16th May 2020, 14:30 – 16:00

**Ensuring Faster Development and Equitable Access: Future Scenarios from Rare 2030**

Chair: TBC